GLPwatch
Papers (12034)
Page 189 of 201, ranked by citation count.
- In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y.
- Methodological and statistical inconsistencies compromise the efficacy and safety analyses of orforglipron.
- Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis.
- Cardiovascular benefits of Tirzepatide: A breakthrough in cardio-metabolic care.
- COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetes.
- Predicting Weight Outcomes From Obesity Medications in a Paediatric Population.
- Combined Treatment of Type 2 Diabetes and Hypothyroidism: Impact of Oral Semaglutide and Levothyroxine on Cardiometabolic and Thyroid Parameters: A 6-Month Comparative Study.
- Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.
- Photodistributed exfoliative dermatitis associated with semaglutide: Expanding the spectrum of glucagon-like peptide-1 receptor agonist-associated cutaneous reactions.
- Formulation Engineering of Oral Semaglutide Tablets: Unleashing Gastric Intestinal Permeation with Sodium Caprate.
- GLP-1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation.
- LiCl-driven direct synthesis of mono-protected esters from long-chain dicarboxylic fatty acids.
- Semaglutide treatment reverses HFD induced hippocampal microglia activation and improves cognitive dysfunction.
- Use of Semaglutide and Tirzepatide in Rheumatic and Musculoskeletal Diseases: Insights on Initiation Patterns and Weight Loss From the Rheumatology Informatics System for Effectiveness Registry.
- Transdermal "Natural GLP-1" Dietary Supplements Violate Law and Place Patients at Risk.
- Glucagon-Like Peptide-1 Receptor Agonists in Managing High Stoma Output: A Scoping Review.
- Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.
- Contractile effects of dulaglutide in the human atrium.
- Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum - Mechanisms, evidence, and future directions.
- GLP-1 medications: use and interest in a representative survey of Finns.
- Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024.
- Tirzepatide for Heart Failure and Obesity.
- Effect of Semaglutide Versus Placebo on Heart Failure With Preserved Ejection Fraction in Obese Patients: A Systematic Review.
- Can tirzepatide transform HFpEF management in Pakistan? A call for action.
- Effect of semaglutide add-on therapy for people living with type 1 diabetes and excess weight.
- Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.
- Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study.
- Correction to: "Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures".
- The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
- Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.
- Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
- Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis.
- Cost-Effectiveness of Access to Obesity Care and Treatments for Adolescents.
- Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.
- Tirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study.
- Revision Medialization Thyroplasty for Glottic Insufficiency Amid Rapid Weight Loss on Semaglutide.
- Depression, cognition, and GLP-1 receptors: Heterogeneity and therapeutic prospects.
- Psychosocial Outcomes in Telemedicine and Long-Acting Incretin-Specific Behavioral Intervention.
- Therapeutic potential of targeting ceramide for early cardiometabolic lipotoxicity in vivo study.
- [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
- A noninvasive <sup>13</sup>C-mannitol breath test to monitor semaglutide treatment-induced delayed oral-cecal transit in mice.
- Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF.
- Mo-Rubbing abdominal improves metabolic homeostasis in type 2 diabetes mellitus mice via a jejunum-specific GLP1-dependent mechanism.
- Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.
- [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
- Semaglutide may reduce cardiovascular disease and heart failure.
- Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
- New Drugs 2019, part 1.
- Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.
- Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses.
- Patient With Tirzepatide-treated Type 2 Diabetes With Difficult Visualization During Esophagogastroduodenoscopy.
- [The role of obesity and weight reduction in obstructive sleep apnea].
- Prevalence of Obesity Medications in the Military Health System: An Update from 2022.
- Evaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non-Diabetic Adults: A Narrative Review.
- Prescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic Status.
- Fast-tracked innovation: orforglipron approval under the FDA's National Priority Voucher program.
- [Liraglutid can support weight loss].
- Pharmaceutical Approval Update.
- Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.
- Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis.